Christophe Bintener

Christophe Bintener
Alzheimer Europe

Master of Arts Gerontology
Communication and dissemination for European research projects & contributing to Alzheimer Europe's outreach activities.

About

7
Publications
5,242
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
88
Citations
Citations since 2016
7 Research Items
88 Citations
20162017201820192020202120220102030
20162017201820192020202120220102030
20162017201820192020202120220102030
20162017201820192020202120220102030
Additional affiliations
January 2017 - February 2022
Alzheimer Europe
Position
  • Project Communications Officer
Description
  • Chris joined Alzheimer Europe as Project Officer in 2017 after finishing his Master of Arts in Gerontology at the University of Vechta (Germany). Since September 2020, Chris has been assigned Project Communications Officer. He collaborates in different European research projects such as Neuronet, LETHE and AI-MIND and contributes to Alzheimer Europe's outreach activities.
October 2015 - April 2016
Cologne University Hospital
Position
  • Research Assistant
Description
  • Main subject of work: Realisation of a computerised cognitive training programme pilot study for elderly people.
September 2011 - September 2015
Institute for Gerontology
Position
  • Research Assistant
Description
  • Main subjects of work: Neuropsychological interventions - especially with elderly people and moral decision-making over the life span.
Education
October 2013 - August 2016
Institute for Gerontology
Field of study
  • Gerontology
October 2010 - September 2013
Institute for Gerontolgoy
Field of study
  • Gerontology

Publications

Publications (7)
Article
Full-text available
Background Dementia outcomes include memory loss, language impairment, reduced quality of life and personality changes. Research suggests that outcomes selected for dementia clinical trials might not be the most important to people affected. Objective One of the goals of the ‘Real world Outcomes across the Alzheimer's Disease spectrum for better c...
Technical Report
Full-text available
Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates for dementia in Europe. The key findings of Alzheimer Europe’s report include: • Across men and women and across most age groups, there has been a reduction in the prevalence of dementia...
Article
Full-text available
In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer's disease (AD) requ...
Article
Full-text available
Introduction: Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of the disease most relevant to key stakeholders. Methods: A systematic review sought research that elic...
Article
Full-text available
ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer’s disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to m...

Network

Cited By

Projects

Projects (5)
Project
The project will characterize cytotoxic lymphocytes in peripheral blood as potential markers for predicting AD and investigate the impact of sleep disturbances on these markers. ADIS aims to identify novel signatures of the immune system and digitally recorded physiology for early prediction of the disease, potentially occurring early in the disease course and associated with rapid clinical decline. The project uses a multidisciplinary approach to multi-omics profiling of the immune system in conjunction with AI and Agent-Based Modeling (ABM). Further goals of ADIS are to: (a) provide new candidate biomarkers and insights into the role of peripheral cytotoxic lymphocytes (specialized immune cells in the blood) in AD; and (b) understand the correlation of immune signatures with digitally recorded pathophysiological disorders, such as cognition and sleep. To this end, the project will collect a large amount of data using single-cell sequencing, flow cytometry, clinical examination, as well as modern digital technologies (augmented reality application, smartwatch), from; 25 healthy individuals, 25 individuals with mild cognitive impairment due to Alzheimer's disease, and 25 people with mild to moderate Alzheimer's disease.
Project
Every three seconds someone in the world develops dementia. There are over 50 million people worldwide living with dementia and by 2030 this figure is expected to reach 82 million. Besides time-consuming patient investigations with low discriminative power for dementia risk, current treatment options focus on late symptom management. By screening brain connectivity and dementia risk estimation in people affected by mild cognitive impairment, the EU-funded AI-Mind project will open the door to extending the ‘dementia-free’ period by offering proper diagnosis and early intervention. AI-Mind will develop two artificial intelligence-based digital tools that will identify dysfunctional brain networks and assess dementia risk. Personalised patient reports will be generated, potentially opening new windows for intervention possibilities. For further details visit: https://www.ai-mind.eu/
Archived project